| Dr Erik Wissner, MD | |
|
3901 Hoyt Ave, Everett, WA 98201-4988 | |
| (425) 339-5411 | |
| (425) 339-5448 |
| Full Name | Dr Erik Wissner |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 25 Years |
| Location | 3901 Hoyt Ave, Everett, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508849340 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 036138888 (Illinois) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD61480639 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Regional Medical Center Everett | Everett, WA | Hospital |
| University Of Illinois Hospital | Chicago, IL | Hospital |
| Whidbeyhealth Medical Center | Coupeville, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Everett Clinic Pllc | 6406752153 | 552 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
Neuroscientists at Georgetown University Medical Center have discovered a brain anomaly that explains why some people diagnosed with autism cannot easily recognize faces - a deficit linked to the impairments in social interactions considered to be the hallmark of the disorder.
National and global public policy needs to change to take into account the social factors behind ill health and reduce the health inequalities seen within and between countries, states an article in this week's issue of The Lancet.
BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.
A novel type of sensor, based on nanometer-scale pores in a semiconductor membrane, is a step closer to practical use in applications such as analyzing the protein contents of a single cell. Researchers pioneering single-molecule nanopore sensor technology at the Technische Universit-t M-nchen (TUM) have shown its potential through a succession of experiments over the past few years.
› Verified 1 days ago
| Entity Name | The Polyclinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174594634 PECOS PAC ID: 2163328196 Enrollment ID: O20031210000788 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
Neuroscientists at Georgetown University Medical Center have discovered a brain anomaly that explains why some people diagnosed with autism cannot easily recognize faces - a deficit linked to the impairments in social interactions considered to be the hallmark of the disorder.
National and global public policy needs to change to take into account the social factors behind ill health and reduce the health inequalities seen within and between countries, states an article in this week's issue of The Lancet.
BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.
A novel type of sensor, based on nanometer-scale pores in a semiconductor membrane, is a step closer to practical use in applications such as analyzing the protein contents of a single cell. Researchers pioneering single-molecule nanopore sensor technology at the Technische Universit-t M-nchen (TUM) have shown its potential through a succession of experiments over the past few years.
› Verified 1 days ago
| Entity Name | The Everett Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831186766 PECOS PAC ID: 6406752153 Enrollment ID: O20031211000922 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
Neuroscientists at Georgetown University Medical Center have discovered a brain anomaly that explains why some people diagnosed with autism cannot easily recognize faces - a deficit linked to the impairments in social interactions considered to be the hallmark of the disorder.
National and global public policy needs to change to take into account the social factors behind ill health and reduce the health inequalities seen within and between countries, states an article in this week's issue of The Lancet.
BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.
A novel type of sensor, based on nanometer-scale pores in a semiconductor membrane, is a step closer to practical use in applications such as analyzing the protein contents of a single cell. Researchers pioneering single-molecule nanopore sensor technology at the Technische Universit-t M-nchen (TUM) have shown its potential through a succession of experiments over the past few years.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erik Wissner, MD Po Box 5127, Everett, WA 98206-5127 Ph: (425) 304-8431 | Dr Erik Wissner, MD 3901 Hoyt Ave, Everett, WA 98201-4988 Ph: (425) 339-5411 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
Neuroscientists at Georgetown University Medical Center have discovered a brain anomaly that explains why some people diagnosed with autism cannot easily recognize faces - a deficit linked to the impairments in social interactions considered to be the hallmark of the disorder.
National and global public policy needs to change to take into account the social factors behind ill health and reduce the health inequalities seen within and between countries, states an article in this week's issue of The Lancet.
BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.
A novel type of sensor, based on nanometer-scale pores in a semiconductor membrane, is a step closer to practical use in applications such as analyzing the protein contents of a single cell. Researchers pioneering single-molecule nanopore sensor technology at the Technische Universit-t M-nchen (TUM) have shown its potential through a succession of experiments over the past few years.
› Verified 1 days ago
Timothy Edward Mcnamara, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1001 N Broadway, Suite A3, Everett, WA 98201 Phone: 425-317-0300 Fax: 425-317-0303 | |
Dr. Madhurina Roy, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9505 19th Ave Se, Ste 100, Everett, WA 98208 Phone: 425-225-6721 Fax: 425-225-6725 | |
Dr. Kavyashri Kodlipet Jagadeesh, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1330 Rockefeller Ave Ste 210, Everett, WA 98201 Phone: 425-261-4940 Fax: 425-261-4932 | |
Amy D Nelson, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2930 Maple St, Everett, WA 98201 Phone: 425-261-1500 Fax: 425-261-1515 | |
Ya-lan Huang, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1330 Rockefeller Ave, Suite 450, Everett, WA 98201 Phone: 425-258-6801 | |
Mahesh Mulumudi, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-339-5411 | |
James M Schmitt, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 12728 19th Ave Se, Suite 200, Everett, WA 98208 Phone: 425-225-2700 Fax: 425-225-2790 |